Mind the gap in clinical practice guidelines—how I treat CLL patients with unmutated IGHV status

Summary The treatment of chronic lymphocytic leukemia has made immense progress in recent years. Nevertheless, different risk constellations persist even with the use of targeted therapies. One of these, unmutated IGHV status, continues to have a prognostic influence. This review discusses the current therapy recommendations and highlights the use of limited therapies and long-term therapies with a particular focus on patients harboring this risk factor.